ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
0.00%
Bitcoin
63,887.08
-0.01%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Ultragenyx Pharmaceutical Inc (RARE)

  7. Ultragenyx Pharmaceutical Inc (RARE) Noticias

RARE Ultragenyx Pharmaceutical Inc

42.75
-0.45 (-1.04%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Ultragenyx Pharmaceutical Inc RARE NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.45 -1.04% 42.75 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
44.88 42.675 46.005 42.75 43.20
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
02/5/202415:00GLOBEUltragenyx Reports First Quarter 2024 Financial Results and..
30/4/202415:00GLOBEUltragenyx Issues 2023 Corporate Responsibility Report,..
30/4/202407:00GLOBEUltragenyx Announces Completion of Enrollment in Phase 3..
25/4/202415:30GLOBEUltragenyx to Host Conference Call for First Quarter 2024..
19/4/202415:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
15/4/202406:00GLOBEUltragenyx Announces Positive Interim Phase 1/2 Data in..
12/4/202415:22GLOBEUltragenyx Announces Update to Conference Call Timing to..
12/4/202407:00GLOBEUltragenyx Announces Upcoming Data Presentations at American..
22/3/202415:00GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
05/3/202419:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202419:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202419:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202419:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202419:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202419:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202419:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202415:30GLOBEUltragenyx to Participate at Investor Conferences in March
23/2/202415:05GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
21/2/202416:03EDGAR2Form S-3ASR - Automatic shelf registration statement of..
15/2/202415:04EDGAR2Form 8-K - Current report
15/2/202415:01GLOBEUltragenyx Reports Fourth Quarter and Full Year 2023..
08/2/202415:00GLOBEUltragenyx to Host Conference Call for Fourth Quarter and..
06/2/202407:00GLOBEUltragenyx Announces Data Demonstrating Treatment with UX111..
05/2/202415:05GLOBEUltragenyx Receives PRIME Designation from European..
25/1/202415:05GLOBEUltragenyx Announces Completion of Dosing Across Stage 1..
19/1/202415:00GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
08/1/202406:00GLOBEMereo BioPharma Provides Update on Pipeline Progress and..
08/1/202405:03EDGAR2Form 8-K - Current report
07/1/202410:00GLOBEUltragenyx Reports Preliminary 2023 Revenue; Guidance for..
04/1/202407:00GLOBEUltragenyx Receives Positive Recommendation from NICE in the..
03/1/202407:00GLOBEUltragenyx Announces Completion of Enrollment in Global..
02/1/202415:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202415:05GLOBEUltragenyx to Present at the 42nd Annual J.P. Morgan..
21/12/202316:45DJNUltragenyx to Pay $6 Million to Settle Alleged False..
21/12/202315:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
21/12/202315:02EDGAR2Form 8-K - Current report
18/12/202307:00GLOBEUltragenyx Receives European Commission Decision for..
20/11/202315:30GLOBEUltragenyx to Participate at Investor Conferences in..
17/11/202315:30GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
07/11/202316:00GLOBEUltragenyx to Participate in the Jefferies London Healthcare..
02/11/202315:17EDGAR2Form 8-K - Current report
02/11/202315:05GLOBEUltragenyx Reports Third Quarter 2023 Financial Results and..
26/10/202315:05GLOBEUltragenyx to Host Conference Call for Third Quarter 2023..
23/10/202315:01GLOBEUltragenyx Announces Closing of Public Offering of Common..
23/10/202305:31EDGAR2Form 8-K - Current report
20/10/202315:00GLOBEUltragenyx Reports Inducement Grant Under Nasdaq Listing..
20/10/202305:31EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18/10/202320:16GLOBEUltragenyx Announces Pricing of Public Offering of Common..
17/10/202315:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
17/10/202315:02GLOBEUltragenyx Announces Proposed Public Offering of Common..

Su Consulta Reciente

NASDAQ
RARE
Ultragenyx Pharmaceutical
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados